Vaccination against hepatitis A in children: A review of the evidence

Therapeutics and Clinical Risk Management

Volumn 3, Issue 6, 2007, Pages 1071-1076

  Bonanni, Paolo ^a   Boccalini, Sara ^a   Bechini, Angela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Effectiveness; Epidemiology; Hepatitis A; Herd immunity; Outbreaks; Vaccination

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ANAPHYLAXIS; ANTIBODY TITER; BRACHIAL PLEXUS NEUROPATHY; BRAIN DISEASE; CHILD; CHILD CARE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ERYTHEMA MULTIFORME; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HEALTH CARE POLICY; HEALTH PROGRAM; HEPATITIS A; HEPATITIS A VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION CONTROL; INJECTION SITE COLORATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MULTIPLE SCLEROSIS; MYELITIS; NONHUMAN; REVIEW; SEROCONVERSION; VOMITING;

EID: 38049108548     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Bell BP, Feinstone SM. 2004. Hepatitis A Vaccine. In: Plotkin SA, Orenstein WA eds. Vaccines. 4th ed. Philadelphia: Saunders. p 269-97.
2. Bonanni P. 1995. Implementation in Italy of a universal vaccination programme against hepatitis B. Vaccine, 13(Suppl 1):S68-S71.
3. Bonanni P, Colombai R, Franchi G, et al. 1998. Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy. Epidemiol Infect, 121:377-80.
4. Bonanni P, Franzin A, Staderini C, et al. 2005. Vaccination against hepatitis A during outbreaks starting in schools: what can we learn from experiences in central Italy? Vaccine, 23:2176-80.
5. [CDC] Centers of Disease Control. 1999. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 48 (RR-12).
6. [CDC] Centers of Disease Control. 2006. Recommended childhood and adolescent immunization schedule - United States, 2006. MMWR, 54(N. 51-52).
7. Chan CY, Lee SD, Yu MI, et al. 1999. Long-term follow-up of hepatitis A vaccination in children. Vaccine, 17:369-72.
8. Connor BA. 2005. Hepatitis A vaccine in the last-minute traveler. Am J Med, 118:58S-62S.
9. Crovari P, Icardi GC, Calcagno P, et al. 1992. Immunogenicity and safety of an inactivated hepatitis A vaccine in young adults. J Prev Med Hyg, 33:111-15.
10. Dagan R, Amir J, Mijalovsky A, et al. 2000. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J, 19:1045-52.
11. Dagan R, Leventhal A, Anis E, et al. 2005. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA, 294:202-10.
12. Fan PC, Chang MH, Lee PI, et al. 1998. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine, 16:232-5.
13. Fiore AE, Shapiro C, Sabin KM, et al. 2001. Persistence of protective antibody concentrations and response to a booster among children given hepatitis A vaccine during infancy: effect of maternal antibody. Proceedings of the 39th Annual Meeting of the Infectious Diseases Society of America (IDSA); Oct 25-28, 2001; San Francisco, USA. San Francisco: Infectious Diseases Society of America: 378.
14. Innis BL, Snitbhan R, Kunasol P, et al. 1994. Protection against hepatitis A by an inactivated vaccine. JAMA, 271:1328-34.
15. Lopalco PL, Malfait P, Menniti-Ippolito F, et al. 2005. Determinants of acquiring hepatitis A virus disease in a large Italian region in endemic and epidemic periods. J Viral Hepat, 12:315-21.
16. Lopalco PL, Salleras L, Barbuti S, et al. 2000. Hepatitis A and B in children and adolescents - what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine, 19:470-4.
17. Malfait P, Lopalco PL, Salmaso S, et al. 1996. An outbreak of hepatitis A in Puglia, Italy, 1996. Eurosurveillance, 1:33-35.
18. Mao JS, Chai SA, Xie RY, et al. 1997. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine, 5:944-7.
19. McMahon BJ, Beller M, Williams J, et al. 1996. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med, 150:733-9.
20. Nalin DR, Kuter BJ, Brown L, et al. 1993. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adults populations: an overview. J Hepatol, 18(suppl 2):S51-5.
21. Piazza M, Safary A, Vegnente A, et al. 1999. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine, 17:585-8.
22. Poland GA. 2005. Evaluating existing recommendations for hepatitis A and B vaccination. Am J Med, 118(10A):16S-20S.
23. Prikazsky V, Olear V, Cernoch A, et al. 1994. Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol, 44:457-9.
24. Purcell RH, D'Hondt E, Bradbury R, et al. 1992. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine, 10(suppl):148-51.
25. Sagliocca L, Amoroso P, Stroffolini T, et al. 1999. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet, 353:1136-9.
26. Shaw FE, Sudman JH, Smith SM, et al. 1986. A community-wide epidemic of hepatitis A in Ohio. Am J Epidem, 123:1057-65.
27. Van Damme P, Mathei C, Thoelen S, et al. 1994. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity. J Med Virol, 44:435-41.
28. Van Damme P, Banatvala J, Fay O, et al. 2003. Hepatitis A booster vaccination: is there a need? Lancet, 362:1065-71.
29. van Gorkom J, Leentvaar-Kuijpers A, Kool JL, et al. 1998. Annual epidemics of hepatitis A in four large cities related to holiday travel among immigrant children. Ned Tijdschr Geneeskd, 142:1919-23.
30. Wasley A, Samandari T, Bell BP. 2005. Incidence of hepatitis A in the United States in the era of vaccination. JAMA, 294:194-201.
31. Werzberger A, Mensch B, Kuter B, et al. 1992. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med, 327:453-7.
32. Werzberger A, Kuter B, Shouval D, et al. 1993. Anatomy of a trial: a historical view of the Monroe inactivated hepatitis A protective efficacy trial. J Hepatol, 18(Suppl 2):S46-S50.
33. Werzberger A, Kuter B, Nalin D. 1998. Six years' follow-up after hepatitis A vaccination. N Engl J Med, 338:1160.
34. Werzberger A, Mensch B, Nalin DR, et al. 2002. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. Vaccine, 20:1699-701.
35. [WHO] World Health Organization. 1995. Public health control of hepatitis A: memorandum from a WHO meeting. Bull WHO, 73:15-20.
36. [WHO] World Health Organization. 2000. WHO position paper on hepatitis A vaccines. Wkly Epidemiol Rec, 75:38-44.
37. Wiens BL, Bohidar NR, Pigeon JG, et al. 1996. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol, 49:235-41.
38. Williams J, Bruden D, McMahon B, et al. 2000. Response to two doses of hepatitis A vaccine administered an average of 27 months apart. Antiviral Ther, 13:5.